KBC Group
SNDX icon

KBC Group’s Syndax Pharmaceuticals SNDX Stock Holding History

KBC Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67K Hold
3,062
– – ﹤0.01% 1611
2026
Q1 		$72K Sell
3,062
-2,118
-41% -$46K ﹤0.01% 1498
2025
Q4 		$109K Hold
5,180
– – ﹤0.01% 1220
2025
Q3 		$80K Hold
5,180
– – ﹤0.01% 1401
2025
Q2 		$49K Hold
5,180
– – ﹤0.01% 1617
2025
Q1 		$64K Sell
5,180
-1,774
-26% -$25K ﹤0.01% 1716
2024
Q4 		$92K Buy
6,954
+3,559
+105% +$60.9K ﹤0.01% 1617
2024
Q3 		$65K Hold
3,395
– – ﹤0.01% 1577
2024
Q2 		$70K Buy
+3,395
New +$71K ﹤0.01% 1420

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

KBC Group's SNDX Position: Q2 2026 in Review

KBC Group held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 3,062 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

KBC Group first reported a position in SNDX in Q2 2024 and has held it in 9 quarters since. The position peaked at $109K in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • KBC Group held 3,062 shares of Syndax Pharmaceuticals worth $67K as of Q2 2026.
  • KBC Group left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1611 holding.
  • KBC Group first reported a position in Syndax Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • KBC Group's Syndax Pharmaceuticals position peaked at $109K in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.